About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (NQ:QNTM)

3.835 -0.015 (-0.39%)
Streaming Delayed Price Updated: 10:09 AM EDT, Sep 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Quantum Biopharma Ltd. - Class B Subordinate Voting Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
Quantum BioPharma Ltd. (NASDAQ: QNTM) Receives FDA Green Light to Move Lucid-MS into Phase 2 Testing
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Licensee Unbuzzd Wellness Appoints Michael “Zappy” Zapolin CEO
Via Investor Brand Network
News headline image
Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO
From Quantum BioPharma
Via GlobeNewswire
Quantum BioPharma Ltd. (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments
Via Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Featured in BioMedWire Editorial on Lucid-MS Phase 2 Trial
Via Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Announces that Rodman & Renshaw Initiates Coverage with Buy Rating, $8 Price Target
Via Investor Brand Network
News headline image
Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target
From Quantum BioPharma
Via GlobeNewswire
News headline image
Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
From Quantum BioPharma
Via GlobeNewswire
NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Featured in NetworkNewsAudio APR Highlighting FDA Clearance of Lucid-MS IND
Via Investor Brand Network
News headline image
NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating ‘Rare Moment’ in MS Research
From NetworkNewsWire
Via GlobeNewswire
News headline image
Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials
From Quantum BioPharma Ltd.
Via GlobeNewswire
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
Via Investor Brand Network
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
Via Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
Via Investor Brand Network
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in BioMedWire Editorial Following FDA Clearance for Lucid-MS Phase 2 Trial
Via Investor Brand Network
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Featured in BioMedWire Editorial Following FDA Clearance for Lucid-MS Phase 2 Trial
Via Investor Brand Network
News headline image
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
From BioMedWire
Via GlobeNewswire
News headline image
Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment
From Quantum BioPharma Ltd.
Via GlobeNewswire
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
Via Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
Via Investor Brand Network
News headline image
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
From BioMedWire
Via GlobeNewswire
NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Draws ‘Buy’ Rating on Lucid-MS Potential
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Moves Myelin-Protecting MS Therapy to Phase 2 Development
Via Investor Brand Network
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Explores Myelin Protection as New Focus in MS Treatment
Via Investor Brand Network
Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves
Via Investor Brand Network
NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2
Via Investor Brand Network
News headline image
Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial
From Quantum BioPharma
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.